By using an improved LRRK2 monoclonal antibody technique, absolute quantification of the LRRK2 protein has revealed elevated CSF LRRK2 levels in G2019S-PD compared to sPD and non-manifesting G2019 carriers [119]. Here, LRRK2 is linked to Platelet storage pool disease.